Moderna Reveals First Data on Its Personalized Cancer Vaccines
Chemicals sit inside a refrigerator at the Moderna Therapeutics Inc. lab in Cambridge, Mass.
Photographer: Adam Glanzman/BloombergThis article is for subscribers only.
Moderna Inc., whose initial public offering in December was one of the most hyped in biotech, gave investors their first look at its personalized cancer vaccine platform on Wednesday.
Twelve of the 13 patients who received Moderna’s mRNA-4157 as monotherapy after their solid tumors had been surgically removed are still disease-free after about eight months, according to an abstract released ahead of the American Society of Clinical Oncology annual meeting. In 20 patients with inoperable tumors, adding mRNA-4157 to Merck & Co.’s Keytruda led to two partial remissions and five patients had stable disease.